TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.9724
-0.0241 (-2.42%)
At close: Feb 11, 2026, 4:00 PM EST
0.9511
-0.0213 (-2.19%)
After-hours: Feb 11, 2026, 5:12 PM EST
TScan Therapeutics Employees
As of September 30, 2025, TScan Therapeutics had 148 total employees, including 146 full-time and 2 part-time employees. The number of employees decreased by 51 or -25.63% compared to the same quarter last year.
Employees
148
Change
-51
Growth
-25.63%
Revenue / Employee
$56,912
Profits / Employee
-$963,500
Market Cap
55.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 148 | -51 | -25.63% | 146 | 2 |
| Jun 30, 2025 | 210 | 22 | 11.70% | 208 | 2 |
| Mar 31, 2025 | 201 | 34 | 20.36% | 200 | 1 |
| Dec 31, 2024 | 195 | 41 | 26.62% | 194 | 1 |
| Sep 30, 2024 | 199 | 44 | 28.39% | 188 | 11 |
| Jun 30, 2024 | 188 | 39 | 26.17% | 175 | 13 |
| Mar 31, 2024 | 167 | 29 | 21.01% | 161 | 6 |
| Dec 31, 2023 | 154 | 16 | 11.59% | 154 | 0 |
| Sep 30, 2023 | 155 | 24 | 18.32% | 145 | 10 |
| Jun 30, 2023 | 149 | 31 | 26.27% | 135 | 14 |
| Mar 31, 2023 | 138 | 33 | 31.43% | 136 | 2 |
| Dec 31, 2022 | 138 | 33 | 31.43% | 137 | 1 |
| Sep 30, 2022 | 131 | 36 | 37.89% | 127 | 4 |
| Jun 30, 2022 | 118 | 43 | 57.33% | 115 | 3 |
| Mar 31, 2022 | 105 | 44 | 72.13% | 104 | 1 |
| Dec 31, 2021 | 105 | 47 | 81.03% | 104 | 1 |
| Sep 30, 2021 | 95 | 37 | 63.79% | 90 | 5 |
| Jun 30, 2021 | 75 | - | - | 73 | 2 |
| Mar 31, 2021 | 61 | - | - | 60 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| ImmuCell | 84 |
| InflaRx | 74 |
| PMV Pharmaceuticals | 47 |
| Instil Bio | 14 |
| Cingulate | 13 |
| Grace Therapeutics | 6 |
TCRX News
- 2 months ago - TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - GlobeNewsWire
- 3 months ago - TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 - GlobeNewsWire
- 5 months ago - TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 - GlobeNewsWire
- 5 months ago - TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire